Role of Thyroid Hormones and mir-208 in Myocardial Remodeling in 5/6 Nephrectomized Rats  by Prado-Uribe, María-del-Carmen et al.
Archives of Medical Research 44 (2013) 616e622ORIGINAL ARTICLE
Role of Thyroid Hormones and mir-208 in Myocardial Remodeling
in 5/6 Nephrectomized Rats
Marıa-del-Carmen Prado-Uribe,a Marıa-Virgilia Soto-Abraham,b Carmen J. Mora-Villalpando,a
Juan M. Gallardo,a Edmundo Bonilla,c Marcela Avila,a Eduardo Tena,a and Ramon Paniaguaa
aMedical Research Unit in Nephrology Diseases, Specialty Hospital, Centro Medico Nacional Siglo XXI, Mexican Social Security Institute,
Mexico City, Mexico
bPathology Service, National Institute of Cardiology ‘‘Dr. Ignacio Chavez’’, Mexico City, Mexico
cDepartment of Health Sciences, Autonomous Metropolitan University, Iztapalapa, Mexico City, Mexico
Received for publication October 23, 2013; accepted October 30, 2013 (ARCMED-D-13-00588).Address reprint re
Investigacion Medica
lidades, Centro Medi
guro Social, Av. Cua
06720, Phone: (þ52)
gmail.com
0188-4409/$ - see fro
http://dx.doi.org/10Background and Aims. Thyroid hormones exert important effects on heart remodeling
through mir-208. The process may have a role in myocardial changes in chronic kidney
disease where thyroid abnormalities are common. In this study the effect of T4 supple-
mentation on left ventricle (LV) remodeling in 5/6 nephrectomized rats (5/6Nx) was
analyzed.
Methods. 5/6Nx rats and 5/6Nx under T4 supplementation (5/6Nx þ T4) were compared
with control (C) and thyroidectomized (Tx) rats. After 8 weeks of follow-up, LV was
analyzed for a-MHC, b-MHC, TGF-b, and mir-208 expression, hydroxyproline content,
and myocardial fibrosis. Serum collagenase activity was also analyzed.
Results. Heart weight increased in 5/6Nx rats compared to C, which was prevented with T4
supplementation (C, 1.5  0.04; 5/6Nx, 1.8  0.09; 5/6Nx þ T4, 1.6  0.07 g, p!0.05).
The same pattern was seen for LV wall thickness, hydroxyproline content, LV fibrosis,
and mRNATGF-b expression (C, 0.47  0.17; 5/6Nx, 10.55  3.4; 5/6Nx þ T4, 3.01 
0.52, p !0.01). Tx rats had reduction in heart weight, increased LV wall thickness, and
fibrosis. Collagenase activity did not change in any group. mRNA expression of a-, b-
MHC, and TGF-b increased in 5/6Nx in comparison to C and 5/6Nx þ T4. Expression
of mir-208 decreased in 5/6Nx groups, and levels were restored with T4 supplementation
(4.21  0.28, 3.39  0.29, and 4.26  0.37 RU, respectively, p!0.01).
Conclusions. Decreased plasma level of thyroid hormones or sensitivity at tissue level
observed in chronic kidney disease induced by 5/6Nx has an important effect in heart re-
modeling processes, some of it related or mediated by mir-208 and TGF-b expression in
the heart.  2013 IMSS. Published by Elsevier Inc.
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Cardiovascular diseases (CVD) are the leading cause of
morbidity and mortality in patients with chronic kidneyquests to: Marıa-del-Carmen Prado-Uribe, Unidad de
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.1016/j.arcmed.2013.11.005disease (CKD), particularly in patients in chronic dialysis
(1e4). Heart failure is one of themost frequent forms of heart
disease in this population; fluid and pressure overload are
among the mechanisms underlying this phenomenon. Func-
tional changes are associatedwith abnormal remodelingwith
heart enlargement and chamber dilatation, particularly of the
left ventricle (LV) where cardiomyocyte hypertrophy and
apoptosis, as well as interstitial fibrosis, occur.
Decreased expression ofa-myosin heavy chain (a-MHC),
overexpression of b-myosin heavy chain (b-MHC), andInc.
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biochemical manifestations of myocardial remodeling.
Myocardial fibrosis is of clinical interest because it contrib-
utes to diastolic dysfunction, one of the early alterations
found in CKD patients (5). Myocardial fibrosis results from
the imbalance between the synthesis and degradation of
collagen molecules (6e8). Genetic factors, cytokines, and
hormones can modify hypertrophy and fibrosis. Among
these, one not-well-understood factor is the reduction in
thyroid hormones, which seems to be part of this complex
mechanism (9,10).
Low or low-normal plasma levels of triiodothyronine
(T3) and thyroxine (T4) with normal thyroid stimulating
hormone (TSH) is the hormonal pattern commonly seen
in CKD patients (9,11). In some studies it has been reported
that low levels of T3 are inversely associated with mortality
rates, both in hemodialysis and peritoneal dialysis patients,
but the nature of the association is unclear (12e15); heart
abnormalities are a possible explanation. Thyroid hormones
are linked with the process of hypertrophy as well as
fibrosis in the heart in several ways (10). Experimental
and clinical studies have shown that thyroid hormones regu-
late expression of proteins associated with hypertrophy
such as a-, and b-MHC and also prevent collagen deposit
and/or increase collagen removal (16e20).
In the past few years, a growing number of reports have
emerged concerning the post-transcriptional regulation of
different proteins in various biological processes. Micro-
RNAs have a central role in this regulation. One of them,
microRNA-208 (mir-208), is selectively expressed in
myocardial tissue and is involved in the control of heart re-
modeling because it regulates the expression of b-MHC and
myocardial fibrosis in response to various stimuli (21,22).
Thyroid hormones are at the same time one of the most
important factors regulating the expression of mir-208 at
the pre-transcriptional level. In spite of their potential as
regulators of myocardial remodeling, thyroid abnormalities
have not been sufficiently studied in terms of myocardial
changes in CKD patients or experimental models of uremia.
The aim of the present study was to analyze the ef-
fect of thyroxin supplementation on expression of mir-
208 as well as of hypertrophy-related proteins and
mechanisms of fibrosis in the myocardium of rats with
induced CKD.Materials and Methods
Animals
Male Sprague Dawley rats weighing 250e300 g were stud-
ied. Rats were allowed free access to standard chow (5008
Purina chow, Purina SA, Mexico) and tap water and were
housed under controlled humidity and temperature with a
12-h light-dark cycle.Experimental Design and Procedures
Four groups of animals with at least eight rats each were
formed. Group C, sham-operated rats, served as controls:
Group 5/6Nx, rats with chronic kidney disease induced
by 5/6 nephrectomy; Group 5/6Nx þ T4, 5/6Nx rats supple-
mented with L-thyroxine; Group Tx, thyroidectomized rats.
5/6Nx was performed as previously reported (23). In
group 5/6Nx þ T4, thyroxin (T4) (8 mg/kg/day) (Sigma
Chemical Co., St. Louis, MO) was administered intraperito-
neally. Hypothyroidism was surgically induced in animals
of Tx group. Rats were anesthetized with xylazine-
ketamine and the thyroid gland was dissected and excised.
Parathyroid glands were dissected and implanted into the
sternocleidomastoid muscles.
Rats were followed for 8 weeks after the last surgery.
Blood pressure was measured weekly by a non-invasive
method in the tail (CODA 2 system model; Kent Scientific
Corporation, Torrington, CT). At the end of follow-up, rats
were weighed and sacrificed using pentobarbital. Blood
samples were taken, plasma was separated and kept frozen
at 20C until biochemical analysis, and the heart was
removed and weighed. Left ventricle (LV) samples were
prepared and stored in 10% formaldehyde and in physiolog-
ical solution until assayed.
Methods of Analysis
Serum samples were assayed for creatinine by standard
methods in a clinical chemistry analyzer (Syncron CX5,
Beckman, Fullerton, CA), and plasma assayed for T3 and
T4 by ELISA with commercial kits (Milliplex Cat RTHY-
30K, Billerica, MA).
Histology
LV fragments fixed in 10% formaldehyde were embedded
in paraffin, cut in 4-mm-thick slices and stained using Mas-
son’s trichromic method (24). Histological analysis was
done using an Olympus BX51 microscope (Olympus Amer-
ican, Melville, NY) at different enlargement degrees and
images digitalized and recorded with a VR Evolution half
cybernetic digital camera (Madison, WI). Image analysis
was done by using a color imaging Image-Pro Plus software
v.5.1. Results are expressed as average of pixels for areas of
fibrosis (stained blue with Masson trichrome) with the
selected color in useful areas that were digitized at 10X re-
corded in 50 fields.
Immunohistochemistry
Expression of transforming growth factor beta (TGF-b) in
LV samples was carried out by conventional technique im-
munoperoxidase assay (ABC) using an anti-TGF-b anti-
body (Santa Cruz Biotechnology, Inc., Santa Cruz, CA).
Immunostained intensity for TGF-b was measured using
color analysis capability of imaging software, positivity
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fibrosis-free areas and measured at 40X to obtain a mea-
surement in pixels of the positivity in the tissue to the anti-
body. Analyses were done in a similar manner and
equipment as light histology.
Tissue Biochemistry and Molecular Biology Analysis
LV samples were homogenized in PBS solution for
biochemical assays. Hydroxyproline was measured in left
ventricle as an indicator of fibrosis (25). Collagenase activ-
ity was detected by gelatin zymography (26,27). This assay
measured collagenase 2 and 9.
Obtaining Left Ventricle RNA
Total RNA was isolated from LV samples homogenized in
TRIzol (Invitrogen, Carlsbad, CA) and quantified (Nano-
Drop, Thermo Scientific, Wilmington, DE) at 260 nm and
then used to obtain cDNA.
Synthesis of mir-208 cDNA and RT-PCR was carried out
with a qRT-PCR mirVana miRNA detection kit (Ambion,
Foster City, CA) according to the manufacturer’s protocol.
The reaction used SYBER GREEN as fluorophore and U6
as normalizing gene and was incubated at 95C for 3 min
followed by 40 cycles of 95C for 15 sec and 60C for
30 sec. All reactions were run in duplicate in a Rotor-
Gene thermocycler (Corbertt R6-3000, Concord, NSW).
TGF-b, a and b-myosin Heavy Chain mRNA
Measurement
Quantitative PCR were carried out in duplicate (Thermal
Cycler ABI Prism 7500, Applied Biosystems, Carlsbad,
CA). Sense and anti-sense primers were as follows:
5’AGCTGCAGACAGAGAACGGC3’ and 5’GCTTTTTGT
CCAGGGCTGCG3’ for a-MHC; 5’GCTGGAGCTGATG
CACCTGT3’ and 5’TCGGCATCTGCCAGGTTGTC3’ for
b-MHC; 5’TCGGGAAGCAGTGCCAGAAC3’ and 5’AG
GAGCAGGAAGGGTCGGTT 3’ for TNFb; and 5’ATGGATable 1. Body weight, blood pressure, creatinine, and thyroid hormones at the e
Group C 5/6N
Body weight (g) 442.8  11.3 414.0 
SBP (mmHg) 137.3  5.85 210.3 
DBP (mmHg) 99.3  6.13 169.3 
Serum Cr (mg/dL) 0.51  0.02 1.36 
T3 (ng/mL) 3.87  0.58 1.96 
T4 (ng/mL) 244.73  80.20 104.99 
C, sham-operated rats; 5/6Nx, 5/6 nephrectomized rats; 5/6NxþT4, 5/6Nx, rats
systolic blood pressure; DBP, diastolic blood pressure; Cr, creatinine.
Each value represents mean  SEM.
ap !0.05 vs. C.
bp !0.01 vs C.
cp !0.05 vs. 5/6Nx.
dp !0.01 vs. 5/6Nx.GAAGGCTGGGGCTCA3’ and 5’TTCCAGAGGGGCCAT
CCACA3’ for glyceraldehyde-3-phosphate dehydrogenase,
which served as a normalizing gene. Reactions were run at
95C for 2 min followed by 40 cycles at 95C for 30 sec
and 52.1C for 30 sec and 72C for 32 sec. TGF-b had an an-
nealing temperature of 61C for 30 sec. Quantification was
done with DCT.
Statistics
Data are reported as mean  SEM. Between-group compar-
isons were done with Student t test; p !0.05 was consid-
ered statistically significant.Results
Rats in all groups had similar characteristics regarding
age, body weight, systolic and diastolic blood pressure,
and serum creatinine before surgical procedures. Rats from
5/6Nx and 5/6Nx þ T4 had similar characteristics in age,
body weight, systolic and diastolic blood pressure, and
serum creatinine levels before hormone supplementation.
Table 1 shows results after 8 weeks of follow-up; there were
no significant differences in body weight among groups.
Both systolic and diastolic blood pressure were increased
in 5/6Nx and 5/6Nx þ T4 rats and showed a slight decrease
in Tx group. Serum creatinine levels rose in both groups of
5/6Nx rats, with and without T4 supplementation, and had a
minor increment in Tx group. T3 and T4 levels decreased in
CKD groups with and without hormone supplementation as
well as in Tx animals when compared to C group.
Table 2 shows macroscopic and histologic data of heart
changes at the end of follow-up. Heart/body weight ratio
increased in rats of the 5/6Nx when compared to animals
in the control group. T4 supplementation partially prevented
this increment. Heart/body weight ratio tended to be lower
in Tx rats. The left ventricle wall was thicker in 5/6Nx rats
than in the control group or in the T4 supplementednd of eight weeks progression of kidney damage
x 5/6Nx þ T4 Tx
11.5 378.9  12.8 407.5  14.1
18.25b 217.8  7.18b 129.5  6.4d
6.29b 176.0  24.9b 93.5  4.95d
0.12b 1.63  0.30b 0.57  0.02a
0.56b 2.07  0.54b 4.65  0.76c
10.65b 78.64  15.89b 190.78  58.48d
supplemented with L-thyroxine; Tx, thyroidectomized rats (n 5 8); SBP,
Table 2. Cardiac histology and immunohistochemistry in rat heart
Control 5/6Nx 5/6Nx þ T4 Tx
Heart weight (g) 1.5  0.04 1.8  0.09b 1.6  0.07a 1.3  0.05a
Heart-body weight 3.38  0.33 4.41  0.72a 4.36  0.66a 3.91  0.78
LV wall thickness (mm) 2912  572 4258  345b 3048  651b,d 3188  622b
Hydroxyproline (mg/g) 11.8  1.1 16.2  1.6a 12.1  0.4c 10.4  1.0
Fibrosis (Px) 418  74 11544  601b 4649  681b,d 1990  158b
TGF-b (Px) 0.47  0.17 10.55  3.4b 3.01  0.52b,c 0.85  0.28
MMP (Px) 103  16 105  7 107  4 104  8
C, sham-operated rats; 5/6Nx, 5/6 nephrectomized rats; 5/6NxþT4, 5/6Nx, rats supplemented with L-thyroxine; Tx, thyroidectomized rats (n 5 8); MMP,
metalloproteinase activity; Px, pixels; LV, left ventricular wall thickness.
Each value represents mean  SEM.
ap !0.05 vs C.
bp !0.01 vs C.
cp !0.05 vs. 5/6Nx.
dp !0.01 vs. 5/6Nx.
619Thyroid Hormones and mir-208 in Myocardial Remodelinganimals. In the Tx group this variable also increased but to
a different extent compared with 5/6Nx rats.
Fibrosis measured by light histology as well as by hy-
droxyproline content was higher in the 5/6Nx rats compared
with controls (Table 2, Figure 1). As in other aforemen-
tioned variables, T4 treatment significantly prevented
fibrosis. Tx animals also showed an increase in fibrosis,
but to a lesser extent than in 5/6Nx groups. Immunostained
areas for TGF-b were greater in the 5/6Nx rats than in either
controls or T4-treated animals (Table 2, Figure 2). TGF-b
was increased in Tx rats, but it was below those values seen
in 5/6Nx rats. Collagenase activity as measured by zymog-
raphy was similar in all groups.Figure 1.Microphotographs of LV tissue stained with Masson trichrome method
In T4 supplemented animals the fibrosis extension much less important.Table 3 shows the gene expression of a- and b-MHC,
which increased in 5/6Nx rats and slightly decreased in
the Tx group when compared to the control group. TGF-
b gene expression changed in the same way and follows re-
sults observed by immunohistochemistry. Expression of
mir-208 decreased in 5/6Nx groups, and levels were re-
stored with T4 supplementation.Discussion
Data herein reported support the concept of low thyroid
hormone levels as an important factor in the pathophysi-
ology of hypertrophy and fibrosis of the myocardium of rats(10X). Fibrosis is clearly seen in LV from 5/6Nx group compared to C rats.
Figure 2.Microphotographs of LV showing TGF-b expression, the indirect immunoperoxidase technique showing positivity in dark brown. Rats from 5/6Nx
group express TGF-b with more intensity than controls. T4 supplementation prevented changes.
620 Prado-Uribe et al./ Archives of Medical Research 44 (2013) 616e622with experimentally induced CKD and that mir-208 medi-
ates hormone action.
Appropriate interpretation of these results needs to
consider several important aspects. The first is the model:
5/6Nx generates a moderate degree of CKD and not severe
(as stage 5 may be in humans) renal failure. The second
important aspect refers to the degree of the effect of CKD
on thyroid hormone levels. In humans, changes in thyroid
hormones are associated with the severity of the primary
disease and comprise a broad spectrum of variations, which
can range from low-normal or slightly low levels in free T3
to severe drops in free and total T3 and T4 with elevated
TSH (28). In this context, the model we analyzed was
limited to moderate CKD and moderate changes in thyroid
hormones. The third aspect to be considered in the interpre-
tation of the results concerns other previously reportedTable 3. Analysis of the expression of mRNAs and mir-208 in the left ventricle
Control 5/6Nx
miRNA-208 (RU) 4.21  0.28 3.39  0.
a-MHC (RU) 0.92  0.06 1.14  0.
b-MHC (RU) 0.92  0.08 1.04  0.
TGF-b (RU) 0.84  0.02 1.14  0.
C, sham-operated rats; 5/6Nx, 5/6 nephrectomized rats; 5/6NxþT4, 5/6Nx, rats
value represents mean  SEM.
Data are expressed as relative units (RU). mRNA expression was normalized to
ap !0.05 vs. C.
bp !0.01 vs. C.
cp !0.01 vs. 5/6Nx.
dp !0.05 vs. 5/6Nx þ T4.
ep !0.01 vs. 5/6Nx þ T4.models to study the effects of thyroid hormones on the
heart. These models have involved drastic changes in thy-
roid hormones, which are achieved through total thyroidec-
tomy or the use of high doses of propylthiouracil (PTU)
in the case of hypothyroidism or the administration of
excessive doses of T3 or T4 for the study of hyperthyroid-
ism. In the present study, the Tx group was used only as
a qualitative reference because the effects of 5/6 Nx on thy-
roid function are not equivalent in magnitude to total Tx.
Furthermore, it should be stressed that the effect of 5/6Nx
on heart is the result of the interaction of many factors
and is not limited to the decrease in thyroid hormone levels.
Reductions in thyroid hormones were found in rats with
5/6Nx, which were partially restored by T4 supplementa-
tion. Changes similar in magnitude were found in other
studies with the same model of CKD. Decrements mayof the rat heart
5/6Nx þ T4 Tx
29b 4.26  0.37c 4.72  0.32c,d
19b 1.03  0.14b 0.81  0.08b,c,e
09b 0.99  0.11 0.86  0.15a,c
17b 0.99  0.10b,d 0.73  0.05b
supplemented with L-thyroxine; Tx, thyroidectomized rats (n 5 8). Each
GAPDH and mir-208 expression was normalized with U6 gene.
621Thyroid Hormones and mir-208 in Myocardial Remodelingappear moderate; however, it has been demonstrated that in
addition to low hormone concentrations, CKD animals also
show tissue resistance to thyroid hormones. Separately or
together, they result in reductions of the activity of
T3-dependent hepatic enzymes (29,30), a biochemical evi-
dence of hypothyroidism.
The macroscopic changes in the heart in the 5/6Nx
group were evident and, as expected, associated with incre-
ments of creatinine levels and blood pressure. Supplemen-
tation with T4 did not produce significant changes in these
parameters; therefore, the effects of T4 on heart should be
considered independent of the degree of impairment of
renal function or changes in blood pressure.
In thoracic aorta banding (TAB), in one of the models
of myocardial hypertrophy, one of the most significant
changes is the shift in the synthesis of a-MHC to b-
MHC; this effect is mediated by mir-208. It is encoded as
a part of a-MHC and they are expressed in parallel. As with
other micro-RNAs, mir-208 impedes the synthesis of pro-
teins, and one of its actions is to block b-MHC expression
by binding to b-MHC mRNA and diminishing translation
and allows that of b-MHC. On the other hand, the presence
of mir-208 is necessary, given that it has been demonstrated
that KO animals for mir-208 with TAB do not change their
patterns of MHC. Nevertheless, the presence of mir-208 is
not sufficient to generate hypertrophy or change the pattern
of MHC by itself, given that animals with overexpression of
mir-208 do not generate changes if there is no additional
mechanical stimulus (31,32). Our results are congruent with
this knowledge. In spite of moderate renal impairment and
a moderate drop in T3 and T4, 5/6Nx animals had signifi-
cantly low levels of mir-208 and increased b-MHC in com-
parison with C group, changes that were not present in 5/
6Nx þ T4 group. Complete disappearance of mir-208 was
not expected in this model because decrements in T3 and
T4 were only moderate and because it is known that a
mature form of mir-208 remains for long periods even
when PTU is administered daily for several weeks
(21,31). Remaining mir-208, together with myocardial
stress originated by fluid and pressure overload, might
allow increments of b-MHC as a manifestation of myocar-
dial hypertrophy.
Profibrotic activity of CKD was described in the 1960s
and seems to be a systemic condition. Serum from uremic
patients promoted fibroblast growth and extracellular
matrix protein deposit in cultured cells (32). Increased
collagen content in the skin of CKD patients is now under
study (33), and increased collagen content of the uremic
heart has been recognized. However, the relationship of
fibrosis with thyroid hormones has not been explored
(34e36). Our data suggest that the existence of a deficient
action of thyroid hormones at tissue level in 5/6Nx rats is a
mechanism responsible for myocardial fibrosis. Increment
in collagen content, both by histological and biochemical
measurement, was seen in LV, an effect that could beprevented by T4 supplementation. Increased synthesis
seems to be the main effect of 5/6Nx because no changes
in collagenase activity could be demonstrated. This finding
does not discard changes in other collagenases or collage-
nase inhibitors. The inverse phenomenon, activation of
myocardial matrix degradation, was seen in hyperthyroid
rats (17).
Our data also suggest the participation of TGF-b in the
observed changes because the TGF-b increment followed
the same pattern as collagen detection. Other evidences
support this relationship. The TGF-b gene has the elements
for thyroid hormone responsiveness (37). Furthermore,
circulating levels of TGF-b have been associated with car-
diac fibrosis in rats with renal failure; however, local syn-
thesis of TGF-b or its relationship with thyroid hormones
has not been studied (38). There are alternative links be-
tween thyroid function and TGF-b. TSH stimulates growth
factor synthesis (39), and reverse T3, which is commonly
elevated in CKD, has been found associated with high
serum levels of TGF-b. We did not explore this fact because
normal TSH is part of euthyroid sick syndrome and reverse
T3 was not measured.
Our study has some limitations. Post-transcriptional con-
trol of a- and b-MHC may be different in rodents than in hu-
mans. Other possible control mechanisms may be important.
It has been reported that mir-208 also acts on b-MHC
through blocking thyroid hormone receptor-associated pro-
tein 1 (THRAP1). This interesting process was not explored
in this study. Changes observed in the 8-week follow-up
period may be different in the long term or be modified by
other comorbid conditions often seen in CKD such as
inflammation and malnutrition. The model used explored a
clean induction of CKD; natural kidney diseases may induce
additional changes in heart remodeling.
In conclusion, rats with 5/6Nx showed decrements of
thyroid hormones that were associated with abnormal
myocardial remodeling such as increased expression of b-
myosin heavy chains, TGF-b, and fibrosis, changes that
were reversed after thyroxin supplementation. mir-208
seems to be an intermediary between decreased thyroid hor-
mones and biochemical and molecular aspects of myocar-
dial remodeling.Acknowledgments
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